In the early 1900s, the renowned hematologist Alexander Maximow observed a curious population of cells in the circulation. Unlike most types of blood cells, these cells could adhere to plastic culture dishes and had many of the cellular habits of fibroblasts 1 . Other researchers subsequently found that these blood-borne fibroblasts are similar, but not identical to, bone marrow stromal cells (BMSCs, also known as 'mesenchymal stem cells') 2, 3 . Some of these circulating cells seem to be multipotent, but their mere existence remains controversial, especially in humans. Even murkier is information on where these cells come from, what they do and what the signals are that cause them to appear in the circulation.
In this issue of Nature Medicine, Hong et al. 4 provide more evidence that bona fide circulating stromal-like stem cells do exist and protozoa and multicellular parasites 1 . This innate process is clearly important for host defense, but whether it also has a role in the development of allergic reactions is controversial.
The TLR4 ligand lipopolysaccharide (LPS), a constituent of Gram-negative bacteria, is also commonly found within inhaled allergens such as pollens, house dust and animal dander. To investigate the contribution of TLR4 to allergic responses, Hammad et al. 2 reconstituted irradiated wild-type or TLR4-deficient mice with either wild-type or TLR4-deficient bone marrow to generate groups of mice that had selective ablation of TLR4 expression on either lung structural cells or hematopoietic cells.
They determined that TLR4 was expressed predominantly on pulmonary epithelial cells and alveolar macrophages 2 . Two-photon dynamic imaging showed, compellingly, that TLR4 expression on airway structural cells was vital for effective migration of dendritic cells. Moreover, TLR4 expression on stromal cells, rather than hematopoietic cells, was required for activation of lung dendritic cells and subsequent priming of allergen specific T helper type 2 (T H 2) response (Fig. 1) .
The authors next asked whether TLR4 expression on structural cells is crucial for initiation of responses to a complex, clinically relevant allergen 2 . They administered house dust mite extract, which is known to contain large amounts of LPS, to chimeric mice 2 . Wild-type mice reconstituted with bone marrow from either wild-type or TLR4-deficient mice developed a robust eosinophilic and T H 2 inflammatory response (including interleukin-5 (IL-5) and IL-13 production). Concentrations of key cytokines known to elicit allergen-driven T H 2 responses, such as thymic stromal lymphopoietin (TSLP), IL-25 and IL-33, were all upregulated in mice that had intact TLR4 expression on the airway stromal cells. In contrast, mice that specifically lacked TLR4 on structural cells did not develop any of these characteristic features of inhaled allergen challenge.
The findings give epithelial cells a pivotal position in the generation of immune responses to inhaled antigen. But how might the findings affect clinical disease?
To address this question, the authors delivered a TLR4 antagonist together with inhaled house dust mite antigen 2 . Not only were eosinophil and T H 2 inflammatory responses reduced to baseline, airway hyperresponsiveness-one of the cardinal features of asthma-was restored to normal. It remains to be seen whether this approach will be successful for other aeroallergens such as animal dander or pollen and whether other chronic features of the disease, such as tissue remodeling, are also successfully treated.
This study is of particular interest in light of recent findings that one of the major house dust mite allergens, Derp2, shares structural homology with a component of the TLR signaling complex 3 . This shared homology may also promote allergic reactions. By mimicking the function of TLRs, Derp2 may function as an autoadjuvant to drive adaptive immune responses.
It is well known that dendritic cells are crucial for the polarization of allergen-specific T H 2 cells, leading to generation of T H 2 cytokines that promote the key pathophysiological features of allergic reactions 4 . However, recent evidence shows that the cytokines IL-33, TSLP and IL-25 are able to directly elicit eosinophilia, T H 2 cytokines and airway hyperreactivity 5, 6, 7 . Interestingly, IL-33 is capable of driving allergic inflammation even in the absence of IL-4 (ref. 8) , and IL-25 exacerbates airway hyperreactivity in the absence of T H 2 cytokines 9 . This group of innate proallergic cytokines is able to promote allergenspecific T H 2 responses via dendritic cell recruitment and activation and, in addition, drives pathology directly, even in the absence of T H 2 cytokines. The study by Hammad et al. 2 provides a mechanism for the generation of IL-25, IL-33 and TSLP-via triggering of TLR4 on pulmonary epithelium (Fig. 1) .
The new findings should open up avenues of research for studying genetic susceptibly to asthma. Studies of polymorphisms in the TLR4 locus hint at an association with asthma susceptibility-particularly in children. However, results have been mixed, and it remains to be seen whether such polymorphisms truly affect asthmatic disease susceptibility and outcome 10 . Furthermore, many asthma susceptibility genes are located within the pulmonary epithelium.
It has long been held that environmental triggers such as infection or pollution exacerbate allergic reactions, and the study by Hammad et al. 2 defines a potential mechanism. In addition, these results challenge the current concept of asthma as a disease of the adaptive immune system and provide evidence that both innate and adaptive immune pathways are involved-opening the door to new therapeutic approaches. volume 15 | number 4 | april 2009 nature medicine report that substance P, a neuropeptide, elicits the appearance of these enigmatic cells in peripheral blood. The authors also show that these cells participate in wound repair 4 .
From the clinical perspective, determining the signals that mobilize cells with potential reparative properties into the circulation and fully characterizing their biological properties and tissue origins is highly relevant. Human trials around the world are testing for the clinical utility of systemic infusion of different cell populations after ex vivo isolation and, often, expansion 5 . But it would be highly preferable to stimulate a naturally occurring process to liberate reparative cells through administration of appropriate factors, thereby abrogating the need for harvest of cells and their subsequent ex vivo manipulation.
Using a corneal injury model, Hong et al. 4 identified substance P as such a factor. The authors homed in on the peptide after finding that its concentration in the circulation increased after injury and was dependent on the size of injury 4 . The authors then queried whether injection of substance P alone, or corneal injury alone, could elicit the appearance of stromal-like cells into the circulation, as assessed by the number of plastic-adherent cells that also expressed a marker characteristic of connective tissue and stromal cells, CD29 + (β 1 integrin subunit) 4 . Both scenarios substantially increased the number of these cells, providing support to the concept that the injured cornea emits at least one signal, substance P, that increases the number of circulating CD29 + cells.
These cells did, in fact, resemble BMSCs, on the basis of their expression of a series of markers, their ability to form cartilage in vitro and their ability to form bone and support blood formation upon in vivo transplantation by established procedures. Unexpectedly, both the CD29 + cells and BMSCs expressed keratin-3, previously thought to be a corneal marker.
Corneal injuries treated either with substance P alone or with autologous CD29 + cells healed at a faster rate than untreated controls, indicating that there is a physiologically relevant effect of elevated substance P concentration and CD29 + cell number in the circulation. Furthermore, prelabeled CD29 + cells were incorporated into the regenerating corneal epithelium (expressing keratin-3) and stroma (expressing α-smooth muscle actin), up to three weeks after injury.
Owing to the similarity of substance P-mobilized CD29 + cells to BMSCs, and to the finding that labeled substance P injected into mice binds adherent CD29 + cells from flushed bone marrow, the authors speculated that these cells originate from bone marrow stroma 4 . On the basis of this assumption, they sought to address not only how substance P might mediate BMSC mobilization into the circulation but also whether it has a role in maintenance of BMSCs within the bone marrow, in the face depletion owing to their mobilization after injury 4 .
In in vitro experiments, they found that substance P induced migration of human BMSCs, increased the expression of several key matrix metalloproteinases (thought to play a part in cell mobilization of hematopoietic cells 6 ) and stimulated proliferation of BMSCs mediated by the extracellular signalrelated kinase-1 and extracellular signalrelated kinase-2 (ERK-1/2) signaling pathway 4 . Lastly, substance P mediated translocation of β-catenin from the cytoplasm to the nucleus, suggesting that the TCF/LEF-β-catenin pathway is active in repopulating the bone marrow stroma. This pathway has been implicated in stem cell self-renewal 7 , but its role has not been rigorously demonstrated for the subset of stem cells present in the BMSC population.
Taking all of the data together, the authors conclude that substance P can induce mobilization of a stromal-like cell that homes to a site of injury and promotes healing 4 . They further suggest that these cells originate from the bone marrow stroma and are able to transdifferentiate into epithelial cells, given the persistence of infused cells in the corneal epithelium and their continued expression of a corneal marker, keratin-3 (ref. 4 and Fig. 1) .
Before this study, the presence of circulating cells with characteristics similar to BMSCs was definitively shown in a number of animal species, although they are exceedingly rare in humans for reasons that are as yet unclear 3 . The relationship of these distinctly adherent, stromal-like cells to another population that has been isolated from human blood by FACS with an antibody specific for osteocalcin (a bone matrix protein) is not yet clear, as these osteocalcin-positive cells have a different cell surface character compared to BMSCs and have been reported to increase in number during pubertal growth and after fracture 8 . But other studies have failed to show the existence of these stromallike cells, most likely owing to differences in methods of isolation and culture (reviewed in ref. 9) .
The data presented by Hong et al. 4 clearly support the notion that circulating stromallike cells do exist. There are many reports 4 , corneal injury releases the neuropeptide substance P (SP) into the circulation. This release, or direct injection of substance P, elicits the appearance of CD29 + (β 1 integrin subunit) cells into the circulation. These blood-borne cells become adherent in plastic culture dishes and are able to form cartilage in vitro and bone in vivo. These cells also participate in healing of the cornea.
Injury
Release of substance P into the circulation 4 have shown the true biological character of the substance P-induced CD29 + cells by in vivo transplantation, the gold standard by which to judge differentiation capacity.
However, it is unlikely that substance P is the sole factor involved in the appearance of CD29 + cells in the circulation after corneal injury, and more complete studies are necessary to determine the full repertoire of factors that participate in this phenomenon. Furthermore, it is yet to be determined whether this reaction to injury is specific to the cornea or whether injury of other tissues requires substance P to liberate stromal-like cells with the same character as those identified by Hong et al. 4 The major unanswered question relates to the origin of the CD29 + cells. The authors provide circumstantial evidence that they arise from bone marrow stroma 4 , and other studies indicate that mesenchymal stem cells can be mobilized from bone marrow by a number of factors and conditions. However, definitive proof is lacking in this study and in others. Part of this irresolution relates to the lack of rigorous criteria applied to the evaluation of the origins of circulating stromal-like cells. To date, it has not been possible to generate animal models in which BMSCs are endogenously and specifically labeled to follow their fate. Currently, there is no BMSC-specific promoter that can be used in lineage-tracking studies to definitively answer the question.
There is a great deal of variability between animal species in the numbers of circulating stromal-like cells, even in the case of injury. How the results of animal studies presented by Hong et al. 4 relate to humans will ultimately determine the potential clinical utility of substance P.
